The European Commission Approves Vertex Pharmaceuticals' Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor) For Cystic Fibrosis Patients Ages 6 Years And Older Who Have At Least One Non-class I Mutation In The Cystic Fibrosis Transmembrane Conductance Regulator Gene

Benzinga · 07/01 11:54
  • ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for this medicine in the world.
  • In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride, demonstrating greater improvement in CFTR function.
  • Approximately 31,000 people with CF in the EU are now eligible for this new highly effective modulator therapy.